MANNKIND CORP Restructuring and Related Cost, Number of Positions Eliminated
MANNKIND CORP (MNKD) reported Restructuring and Related Cost, Number of Positions Eliminated of 198 Employee for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2016-03-15
- 2015-09-30: Restructuring and Related Cost, Number of Positions Eliminated 198.00 Employee; Restructuring and Related Cost, Number of Positions Eliminated 9 month 198.00 Employee.
- 2011-02-10: Restructuring and Related Cost, Number of Positions Eliminated 0 month 257.00 Employee; Restructuring and Related Cost, Number of Positions Eliminated 1 month 257.00 Employee.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated | Restructuring and Related Cost, Number of Positions Eliminated 0 month | Restructuring and Related Cost, Number of Positions Eliminated 1 month | Restructuring and Related Cost, Number of Positions Eliminated 9 month |
|---|---|---|---|---|
| 2015-09-30 | 198.00 Employee 10-K · filed 2016-03-15 | 198.00 Employee 10-Q · filed 2015-11-09 | ||
| 2011-02-10 | 257.00 Employee 10-K · filed 2014-03-03 | 257.00 Employee 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |